Here’s an excerpt from the Healthline summary from the recent ADA conference:
Ultra-Rapid Lyumjev: Eli Lilly announced on June 15 that it obtained FDA clearance for its ultra-rapid insulin, Lyumjev (pronounced LOOM-jehv). Clinical trial data from 2019 shows this is faster than existing injected insulins, clocking in at 13 minutes compared to Humalog and other meal-time insulins that take as long as 27 minutes to start impacting glucose levels. It’ll be sold in 10 mL vials and also prefilled KwikPens, both in 100 units/mL and 200 units/mL concentrations. Lyumjev is not approved for use in insulin pumps, but Lilly’s aiming to submit to FDA for insulin pump use later in 2020. Right now it’s for adults only, as pediatric studies remain ongoing. Lilly plans to begin shipping ASAP, but unfortunately does tell us this insulin will have the same ~$300 retail list price as Humalog. It will be included in the Lilly Insulin Value Program that offers eligible patients to get this insulin and others for as low as a $35 monthly co-pay.